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Abstract
To evaluate the role of both oxidation and inflammation in atherosclerosis, we compared LDL oxidizability, in vivo lipid and 
cholesterol oxidation, and basal and lipopolysaccharide (LPS)-stimulated production of various cytokines in normolipidemic 
patients with diabetes mellitus (DM; n = 11), cigarettes smokers (n — 12) and controls (// «= 14). In addition, the effects of vitamin 
E (600 I.U./day for 4 weeks) on these parameters were evaluated. Initial LDL oxidation characteristics before and after vitamin 
E were identical in the 3 groups. Plasma thiobarbituric acid reactive substances were higher in DM and smokers versus controls 
(0.77 ±  0.22, 0.74 ± 0 .14  versus 0.62 ± 0 .10  //mol malondialdehyde equivalents/1, respectively; P versus controls <0.05) and 
normalized after vitamin E supplementation. Total plasma oxysterols were higher in smokers versus controls (354 ±  104 versus 
265 ±  66 nmol/1, P <  0.05) and unaffected by vitamin E. The basal and LFS-stimulated levels of interleukin-1// and tumour 
necrosis factor a (TNFa) and the basal level of interleukin-1-receptor antagonist (IL-1RA) were identical fot 
LPS-stimulated IL-1RA was higher in DM versus controls (10.7 ±  2.0 versus 8.1 ±  1.7 pmol/1, P <0.05). After
in controls and smokers, and IL-1RA in smokers only. Results suggest increased in vivo t •" ess «.md
inflammation in DM and smoking, which is partly overcome by vitamin E. © 1997 Elsevier Science Ireland Ltd
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1. Introduction
The role of oxidative modification of LDL in the 
process of atherogenesis has been made likely by a
of observations in in vitro models, in animal 
models and in humans [1,2]. Oxidized LDL present in 
atherosclerotic lesions is taken up avidly by monocytes 
rendering them into foam cells and induces chemotaxis 
of monocytes [1- 5]. These observations together with 
observation that antioxidants can inhibit the oxida­
tive process hold promise for the development of new 
means of prevention of atherosclerosis [6 9]. Indeed, in 
animal models anlioxidants have been shown to retard
- W ,
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suits have not always been confirmed [13,14]. Beneficial 
2cts are also suggested by the results of observational 
studies in humans, but intervention studies are negi 
so far, or still on the way [15 21].
Atherosclerosis resembles a chronic inflammation in 
which immunocompetent cells are involved and cytoki­
nes are secreted [22,23]. In vitro, activation o f monotiu-
5]. Importantly
»* t1
it 4c *1 * i
enees cytokine release by monocytes [22,23,26
have to
monocyte adhesion to endothelial cells and 
tive potential of cells in the vascular wall,
a-
ing early atherogenesis [22,23]. In addition, oxidized
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L.D.L is immunogenic which is reflected by the presence 
of antibodies against oxidized LDL both in the 
atherosclerotic lesion and in the circulation [31-34].
Participants all underwent a brief physical examina­
tion, after which blood was taken after an overnight 
fast for the assays indicated below. Then they received
The titer of the latter has been found to be related to 
vascular disease [32,34].
Oxidation of lipoproteins is supposed to be a hall­
mark in atherosclerosis related to common risk factors 
for cardiovascular disease, such as hypercholes­
terolemia, diabetes mellitus and cigarette smoking [1]. 
In diabetes mellitus and in smokers, the oxidative stress
D L - a -tocopherol acetate (vitamin E; Organon, Oss, The 
Netherlands) 600 mg (600 I.U.) per day in 3 equal doses 
for 4 weeks, after which blood sampling was repeated. 
Adherence to vitamin E was checked by tablet counting 
and amounted on the average to 98%. The protocol of 
the study was approved by the local medical ethical 
committee and written informed consent was obtained
and LDL-oxidizability is increased [35—39]. There are from all participants.
indications that this oxidative stress can be attenuated
by antioxidants or by improvement of metabolic con- 2.2. Isolation and storage o f  plasma
trol [6,40,41],
So far, no studies have been reported which evaluate 
both parameters of oxidative and inflammatory pro­
cesses. To evaluate the role of these 2 processes and 
their interrelationship in diabetes mellitus and cigarettes 
smokers, we evaluated LDL oxidizability, parameters 
of in vivo lipid and cholesterol oxidation and parame­
ters of inflammation in individuals with these condi­
tions and in controls. In addition, we evaluated the
After an overnight fast, blood was collected in vac­
uum tubes in EDTA (final concentration: I mg/ml). 
Plasma was separated from cells by centrifugation. 
Plasma samples were stored after the addition of sac­
charose as cryopreservative (final concentration 6 g/1) at 
80°C up to 12 months until further analysis of 
parameters indicated below. Storage conditions were 
identical for each study group. Plasma samples for the
effect of treatment with the antioxidant vitamin E on 
these parameters.
determination of cholesterol oxidation products were 
additionally supplemented with butylated hydroxy-
toluene (250 mg/1) before storage.
2. Methods 2.3. Measurement o f LD L oxidation
2.1. Study design LDL was isolated by a short-run ultracentrifugation
Volunteers were recruited from the outpatient clinic 
and from the healthy population. They were between 18 
and 70 years of age, without hypertension or hyperlipi-
procedure, essentially as described in [42]. We have 
shown earlier that storage under the conditions indi­
cated does not influence isolation of LDL and the 
analyses indicated below [42]. The formation of conju-
demia (serum cholesterol less than 6.5 mmol/1, fasting ■gated dienes during copper-mediated oxidation of LDL
less than 2.3 mmol/1, HDL-cholesterol was performed essentially as described [42,43]. From
more than 0.9 mmol/1 in men, more than 1.0 mmol/1 in the resulting curve the following parameters were deter-
women). They were not using any lipid lowering drugs, 
vitamin E or hormones apart from oral contraceptives
mined: (1) the lag time, which equals the time elapsed 
until the rapid increase of the absorbance; (2) the
or insulin. Diabetes mellitus patients all had non-insulin 
dependent diabetes mellitus, and were treated with oral 
drugs (glibenclamide: n =  2; glibenclamide and met-
maximum rate of dienes formed, which is calculated 
from the maximum rate of change in absorbance; and 
(3) the maximum absorbance achieved [42,43],
formin: n =  2; metformin and acarbose: n — 1; subcuta­
neous insulin: n =  6. The duration of diabetes ranged 2.4. Oxysterols in plasma
from 3 to 24 years (mean 10 +  7 years, median: 8 
years). Smokers smoked at least 15 cigarettes per day, Cholesterol oxidation products were determined by a
the average daily consumption amounted to 24 modification of a method described previously [44,45].
cigarettes. All other individuals were non-smokers. Plasma aliquots were thawed at room temperature and
Three diabetes patients had established coronary artery 
disease (previous myocardial infarction, coronary an-
19-OH-choIesteroI was added as internal standard. 
Cholesteryl esters and oxysterol esters were hydrolyzed
gioplasty and stable angina pectoris, respectively). In by saponification for 1 h at 37°C with 0.4 N ethanolic
the group with diabetes mellitus 3 out o f 6 women were 
premenopausal, none were taking oral contraceptives; 
in the smokers group, 7 out of 8 women were pre-
KOH. Lipids were extracted with hexane. Separation of 
cholesterol from oxysterols was achieved by solid phase 
extraction and HPLC. The oxysterols were derivatized
menopausal, 3 taking oral contraceptives and in the with Af,0-bis(trimethylsilyl)trifluoroacetamide for 30
controls, 1 out of 6 women was premenopausal; she min at 60°C. evaporation under
was not taking oral contraceptives. residue was dissolved in hexane and analysed by gas
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chromatography with a 25m x 0.20 3. Results
mm HP-Ultra column (d.f. =  0.11 // m; Hewlett Pack­
ard model 5890) with Helium as carrier at a flow rate 
of 0.7 ml/min. The GC was connected to a mass 
selective detector (MS, Hewlett Packard model 5971). 
The MS was operated in the selected ion monitoring 
mode. The detection limit was 0.2 fmol/injection vol­
ume of 2 //l. The ions used for analysis and typical 
retention times (in 
follows:
fo 1' were as
ene 3//, 19-diol, 353, 27.7; 5,6a-
epoxy-5a eholestan-3a-ol,
3 //, 7ß  diol, 456, 29.1; 5a- eholestan-3//,5,6//~triol, 403, 
33.2; cholcst-5, 3//-ol, 7-one, 472, 33.9; and eholest-5 
ene 3//, 25-diol, 131, 35.2.
3.1. Characteristics o f  the study population
Characteristics of the study population are given in 
Table 1. Age, body mass index (BMI), total choles-
terol, LDL and HDL were
comparable, as were vitamin E levels in plasma and in
LDL and after supplementation. The basal
in the patientswere s
with diabetes mellitus and in s ;rs than in controls.
3.2. Effects o f vitamin E on vitamin E content 
plasma and LDL
2.5. Basal and LPS induced levels o f  cytokines I L - 1/1, 
TNFoc and 1L-1 receptor antagonist in whole blood
Levels of cytokines IL-l/i, TNFa, IL-1RA in whole 
blood both with and without stimulation with LPS 
were assayed as described [46,47], Briefly, blood col­
lected in EDTA (final concentration 1 mg/ml) was 
incubated with and without LPS in the presence of 
aprotinin at 37°C for 24 h, after which the cell super- 
natants were isolated for a further cytokine assay. 
Cytokines IL-l/i, TNF-a and IL-IRA were measured 
with specific radio immuno assays, developed in our 
institute [46,47].
2.6. Other measurements
ation with vitamin E resulted in a 2- to 
increase in the concentration of vitamin E in 
plasma, and a 2-fold-increase in that in LDL (Table 
2). BMI, fasting blood glucose, HbAlc and lipid levels 
were unchanged after vitamin E as compared to the 
values before intervention.
3.3. Initial values o f  parameters o f  LDL oxidizability 
and lipid oxidation and the effects o f vitamin E
Parameters of LDL oxidizability before 
supplementation with vitamin E are given in Table 2. In 
basal conditions, no differences between groups were 
found for lag time, maximal rate of diene formation 
and maximum dienes formed. As expected, after vita-
Thiobarbituric reactive substances
plasma were determined using a fluorescence
Table 1
Characteristics, basal lipids and glucose levels of the 3 studied groups
— .--Vr'-- I*' ' i  I • — iK'rt*' "fcA *• • i t' I ■ T •"■r-T"'1* ÏMrt*,- - *1—h--yj.,* ( 7  V. t •, H • VA •ffi'l • 11 X ^  Ofctf >. JJÍ A. I«’ I  "  .I» ,.!1," !
as 491. Vitamin[48]
plasma and LDL were assayed on an HPLC
in
, The
a í '
by enzymatic
and triglycerides were measured
(CHOD-PAP reagent no. 
237574, Boehringer, Mannheim, Germany; and Sera- 
Pak, Miles, Milan, Italy, respectively). I IDL-choles- 
terol was determined in plasma after precipitation of
oteins with polyethylene glycol-6000 [51]. 
Lp(a) was measured with a specific radioimmunoassay
100, Pharmacia Diagnostics,■olein (a) 
Uppsala, Sweden).
2.7. Statistical evaluation
Statistical evaluation was
s /- ¡md unpaired data. A 2-sided
P < 0.05 was considered to 
expressed as mean + S.D.
,’e
Controls
ií.jimI ix-cn .I-*-- s' u i, V- -r -.-r é i-!---
Diabetes Smokers
H 14 11 12
Male/female 8/6 5/6 4/8
Age (years) 57 ±  14 52 ± 11 49 + 12
BMI (kg/in’) 24.0 + 3.3 25.3 + 2.2 24.7 + 5.0
Weight (kg) 73.6 ±  15.2 73.0 ± 10.0 71.7 + 14.4,
Cholesterol 5.3 ±0 .8 5.2 + 0.8 5.6 -I 0.8
(mmol/l)
Triglycerides 0,9 1 0.3 1.5 + 0.7* 1.4 H-0.5*
(mmol/l)
111)l,-choles- 1.47 + 0.33 1.35 + 0.32A h i 1.24 + 0.39♦J U fLi
terol (mmol/ 
1)
LDL-oholex- 3.6 + 0.7fMiariM 3.4 ± 0 .8 3.9 + 0.7
torol (mmol/ 
1 )
Lp(a)u (mg/1) 185 (16 1050) 260 (122 840) 210 (16 13i
Fasting glucose 4.9 +  0.5 11.7 ± 3.0** 5.0 ±  0.5
(mmol/l)
H bA lc (%) • • • , : .  - 9.1 f 0.9*  m A * » . . ! • • • •  .¿
.* i, *»< • - • • i l , . ¿ , . i i - ......... .. . . .  - .•••.. . i • • *- *• a 1.1‘ • '  -  • .-1 j i  .• ((. , _ ,.- -r -, : 1.4. • • • ,4 « w itx  • • *r \  >** * - »— * ^ .i- <r *
'\L' s are mean MTI U J  «
u Expressed 
* P vs. e
as median and (r<
0.05; ** P vs.
. ni*. -••.. r .• i*. • .—- v  f
'  < controls, P vs. smokers < 0 .001.
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Table 2
Vitamin E concentrations, LDL oxidation characteristics and plasma TBARS before and after suppletion with vitamin E in the groups studied
Initial values 
Vitamin E (mg/1 plasma) 
Vitamin E (mg/mg LDL) 
Lag time (min)
Maximal rate“
Maximal dienes formedb 
TBARSC
After vitamin E
Vitamin E (mg/1 plasma) 
Vitamin E (mg/mg LDL) 
Lag time (min)
Maximal rate“
Maximal dienes formedb
TB A RSC
Results are mean + S.D.
Controls (n — 14)
26 ± 6  
14 + 4
99 ±  23 
14 ± 3  
835 ±  119 
0.62 +  0.10
5 2 + 1 8  
27 ± 9  
146 ±  14**
1 1  +  2 *** 
787 ±  104 
0.57 + 0.18
Diabetes (n =  11)
29 +  8 
1 1 + 4  
97 +  19 
14 +  2 
765 +  111 
0.77 +  0.22*
66 + 21 
25 +  12 
147 +  29**
11 +  3*** 
771 +  123 
0.63 + 0.21***
Smokers (w =  12)
26 +  6 
13 + 3 
1 0 2  +  16 
12 + 2 
760 +  115 
0.74 +  0.14*
57 ±  17
22 +  7 
128 ±28***
1 1  2  
750 + 94 
0.56 +  0.15****
•A % V W  v *  «*• V W v 4 w v f  4 1 ^  «
“ In nmol dienes/mg LDL/min; b in nmol dienes/mg LDL; c in //mol MDA equivalents/1.
* P vs. controls<0.05; ** P vs. initial value<0.001; *** P vs. initial value<0.01; **** P vs. initial value<0.05.
min E supplementation the lag time increased in all 3 
groups, the change being the smallest in the smokers. 
The maximum rate of dienes formed decreased in con­
trols and patients with diabetes, but was unchanged in 
the smokers. Vitamin E did not influence the maximum 
amount of dienes formed.
TBARS concentrations in plasma of diabetes patients 
and smokers were significantly higher than in controls. 
After vitamin E treatment there was a significant drop 
in concentration of TBARS in both diabetes patients 
and smokers, to values comparable to those of the 
control subjects.
Oxysterol concentrations of 5 oxysterols in the vari­
ous groups before and after vitamin E supplementation 
are given in Table 3. Before vitamin E supplementation 
the total amount of oxysterols was higher in smokers 
than in controls, due to higher concentrations of both 
5,6a-epoxy-5a cholestan-3a-ol and cliolest-5, 3/?-ol, 7- 
one. After vitamin E suppletion, only 5,6a-epoxy-5a 
cholestan-3a-ol was found to be significantly decreased. 
In diabetes patients, initial concentrations were no dif­
ferent from those in controls, whereas after vitamin E 
supplementation levels of cholest-5 ene 3/? 7/?-dioI, 
5a-cholestan-3/?,5,6-triol and cholest-5, 3/?-ol, 7-one 
had decreased significantly.
effects o f
o f  IL - lß
The basal and LPS induced levels of the various 
cytokines in the studied groups and the effects of 
vitamin E on these parameters are given in Table 4. 
Unstimulated levels of IL-1/?, TNFa and IL-IRA be­
fore and after vitamin E supplementation were com­
parable within groups, except for the IL-IRA level in
the smokers after vitamin E suppletion, which was 
higher than that in control subjects. After LPS stimula­
tion, the level of each cytokine increased as expected. 
Before vitamin E supplementation, LPS-stimulated lev­
els of IL-IRA were higher both in smokers and patients 
with diabetes mellitus than in controls. After vitamin E  
supplementation, the LPS-induced release of TN Fa and 
IL-IRA dropped significantly in smokers and that o f  
TNFa in controls, IL-IRA reaching levels in controls 
and smokers which were significantly lower than in 
diabetes patients.
4. Discussion
In the current study, parameters of in vitro oxidiz-
ibility of LDL, in vivo acid and cholesterol
oxidation and basal and LPS-induced levels o f  cytoki­
nes were evaluated in patients with diabetes mellitus, in 
cigarette smokers and in controls. In addition, the 
effects of vitamin E on these parameters were evalu­
ated.
In each group, supplementation with 600 I.U. vita­
min E per day during 4 weeks resulted in a comparable 
increase in the plasma vitamin E level by 2- to 3-fold 
and in LDL by 2-fold. Basal levels of vitamin E and the 
observed increase is grossly in accordance with other 
studies [6,7,15,52,53]. Vitamin E supplementation had 
no effect on lipid levels or glycemic control.
LDL oxidizability before vitamin E supplementation 
was comparable in the 3 groups studied. In studies on  
patients with diabetes mellitus, both increased and un­
changed LDL oxidizability has been observed as com ­
pared to controls. An increased oxidizability has been 
postulated to be related to the presence of small dense
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Table 3
Plasma concentrations o f oxvs s before and al'tei •  A4 s ta t io n  with vitamin E (600 I.U./day) for 4 weeks
Oxysterol concentration (nmol/1)
Cholest-5 ene 3ß  7/f-diol
Initial value 
After vitamin E
5,6a-epoxy-5a cholestan-3a-ol 
Initial value 
After vitamin E
5 a - c h o 1 e s t a n - 3 /, 5,6 -1 r i o I
Initial value 
After vitamin E
cholest-5, 3/)‘-ol, 7-onc
Initial value 
After vitamin E
cholest-5 ene 3/>’, 25-diol 
Initial value 
After vitamin E
Total oxysterols 
Initial value 
After vitamin E
38.4 ±  12.3 
37.7 +  12.9
51.0 + 18.6
56.4 + 18.1
29.3 + 7.3
36.7 + 17.7
121 + 3 8
26 + 41
25.6 ±  7.9 
22.8 + 6.8
265 ±  66 
269 + 55
Controls (/; =  13) Diabetes (n = 10)
47.1 ± 2 4 .9
35.8+11.4*
49.1 +  14.1
48.2 +  15.8
36.6 +  38.6■«« »«a
2 6 .0 +  17.6*
166 +  1 2 0
120 +  64*
T7 <¡ +  c 7
■ém  A M  «  >riji Í
21.8 +  5.1
321 +  191 
252 +  98
Smokers {n — 12)
42.2 ±  12.8 
40.8 + 14.9
71.5 ±23.3**
55.6 +  20.0***
36.9 +  16.4 
31.7 + 13.2
181 ± 81**m H u
135 ±  66
2^ 5 4 - 3 8Tr,j , * 7  *  M
"H I 4- 3 ¿1
A u f ¿ m t % 1  I » r  ^  I
354 ±  104** 
285 +  102
■ HW|I
* P < 0.05 vs. initial value; **/><0.05  vs. control group; *** PcO.Ol vs. initial value.
LDL, as found in diabetes mellitus patients with hyper­
triglyceridemia [40,54]. We studied normolipidemic pa 
tients only, possibly explaining the lack of difference. In 
smokers, parameters of LDL oxidizability were no dif­
ferent from controls, confirming the results of others 
[6].
vitamin E supplementation the lag time in­
creased by 50% as expected, and, although the response 
was smaller in the smokers group, there were no signifi­
cant differences between the studied groups. Results of
changes in lag time are well in accordance with 
change in the vitamin E content in LDL, as reported by
?s indicate that neitherPrineen el al. [6]. These fi 
smoking nor diabetes mellitus influences the effects of
vitamin E supplementation on parameters of LDL oxi-
The elevated concentration of TBARS in diabetes 
mellitus and smokers contrasts with the observed unal­
tered susceptibility to in vitro oxidation of LDL. It 
suggests that the in vivo oxidation is not reflected by 
the in vitro oxidizability of LDL. It might point to­
wards shortcomings of the method evaluating in vitro 
oxidizability o f LDL, or to the presence of other oxida­
tion processes apart from those related to circulating 
LDL occurring in vivo.
¡ilysis of TBARS in plasma is a widely used
the evaluation of lipid peroxidation. In 
order to evaluate another parameter of oxidative stress, 
which aims at the evaluation of free radical-dependent
cholesterol oxidation rather than that of fatty acids, we
in plasma. We postulated thatmeasui
from
The concentration of products of fatty acid peroxida­
tion, as measured by TBARS in plasma was higher in 
both diabetes patients and smokers than in controls. 
This may indicate the presence of increased oxidative 
stress in these two groups [9,37,55]. In diabetes patients 
increased levels of TBARS are probably related to an 
enhanced lipid peroxidation by the high glucose levels
itself and to generation superoxide anion
[36,37,56]. In accordance with studies on the effects of 
antioxidants in diabetes patients and diabetic rats, we
cl in
*<
of TBARS
vitamin E treatment [40,41]. Increased concentra­
tions of TBARS in plasma of smokers have been found 
by others [57]; normalization of the concentration after 
vitamin E is in accordance with its effect on
smoking [9],
proteins and cell 
marker of in vivo oxid 0c
s, can serve as an additional 
stress,
both human and rabbit atherosclerotic plaques [58,59] 
have been shown to exert biological activities, as re­
viewed by Smith el al. [60]. There have been reports on 
cytotoxicity of 
5,6a-epoxy-5a
to s
induction of cytokine release by macrophages [61 64]. 
Eventually, cell injury caused by incorporation of oxys­
terols into cell membranes can lead to the disruption of
7 - f f - OH  
an-3a-ol and 25-OH
md endothelial cells and the
ph aggregation,
of LDL into the arterial wall [65].
hypothesized that s are of i
and penetra-
\  it is 
mce in rela-
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Table 4
Results o f basal production and production after incubation with LPS of various cytokines in whole blood, and the effects of vitamin E 
supplementation (600 I.U./day) for 4 weeks
Controls Diabetes Smokers
IL-iyj (pmol/l)
Initial value, no LPS 
After vitamin E, no LPS 
Initial value, with LPS 
After vitamin E, with LPS
0.052 ±  0.009 
0.052 ±0.011  
6.2 ±  4.0 
6.4 ±  2.9
0.048 ±  0.008 
0.045 ±0 .010  
7.2 ±3 .1  
6.8 ±  3.3
t
0.051 ± 0 .0 1 4  
0.048 ± 0 .011  
7.3 ±  1.7 
7.1 ± 3 .5
TNFoc (pmol/l)
Initial value, no LPS 
After vitamin E, no LPS 
Initial value, with LPS 
After vitamin E, with LPS
0.075 ±  0.025 
0.080 ±  0.035 
4.9 ± 2 .1
3.8 ±  1.6*
0.068 ±0.017  
0.070 ±0 .015  
3.9 ±  1.0 
4.6 ±  1.5
0.085 ±  0.028 
0.085 ±  0.035 
4.5 ±  2.2 
3.1 ±  1.0*-**
IL-1RA (pmol/l)
Initial value, no LPS 
After vitamin E, no LPS 
Initial value, with LPS 
After vitamin E, with LPS
0.10 ±  0.04
0.10 ±  0.03
8.1 ±  1.7
7.2 +  1.8
0.13 ±0 .07  
0.13 ±0 .08  
10.7 ±2.0****  
10.5 + 2.1*****
0.15 ± 0 .0 9
0.16 ±0 .08***
9.9 ±  1.9***
8 8 + 1 1  ********
Results are mean ±  S.D.
* P vs. value before vitamin E<0.05; ** P vs. diabetes mellitus <0.05; *** P vs. controls <0.05; **** P vs. controls<0.01; ***** p  vs. controls 
< 0.001.
tion to oxidative stress and inflammation. Hitherto, in 
intervention studies with antioxidants, plasma concen­
trations of oxysterols have not been studied before. In 
the current study, we found higher initial oxysterol 
concentrations in the smokers compared to controls, 
but not in the diabetes patients. The sample size of the 
groups studied may have been too small to detect 
differences in the diabetes patients, since there was a 
trend towards higher oxysterol levels in this group.
The inflammatory status, as reflected by circulating 
and LPS stimulated cytokine production showed no 
differences in levels of IL-1/? and TNFa, whereas there 
was an increased LPS-stimulated level of IL-1RA in 
both patients with diabetes and smokers versus con­
trols. Increased levels o f the cytokine IL-1RA have 
been observed in the acute phase of meningococcal 
disease and in rheumatoid arthritis, and is supposed to 
reflect an antiinflammatory reaction [66,67]. Thus, the 
results of IL-1RA levels in our study would indicate an 
increased inflammation in patients with diabetes melli- 
tus and in smokers. This might be due to the increased 
oxidative stress, to hyperglycaemia and to toxic sub­
stances in cigarettes, but can also reflect an initiation of 
inflammation related to cardiovascular disease. Obvi­
ously, we were not able to correct for these variables. 
Supplementation with vitamin E partly corrected the 
increased IL-1RA response in smokers, but not in 
patients with diabetes mellitus. If the above hypothesis 
were true, this reflects a sustained stimulation of the 
inflammatory system, despite a decreased lipid peroxi­
dation. The latter could be related to hyperglycaemia.
In summary, our data show elevated peroxidation of 
lipids and increased ex vivo LPS stimulated IL-1RA
activity in patients with diabetes mellitus and in smok­
ers and increased oxysterol levels in smokers, whereas 
the susceptibility of LDL is no different from that of 
normal controls. Vitamin E normalizes the differences 
with normal controls, except from the increased LPS 
stimulated IL-1RA activity in diabetes patients. Results
a role for in vivo oxidative stress in both 
conditions, but in diabetes patients stimulation of infl­
ammation is possibly mediated by additional processes 
also, hyperglycaemia being a good candidate.
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